This framework shifts the basis of AD diagnosis in living patients from clinical signs and symptoms to ATN biomarkers (β-amyloid (A), phosphorylated tau (T) and neurodegeneration (N) markers), measured with functional brain imaging techniques (MRI, FDG-PET, PET imaging of synaptic vesicle glycoprotein 2A (SV2A) radioligands, single-photon emission computerised tomography (SPECT) and quantitative EEG) and in blood or CSF samples. Here, MAPT is linked to Alzheimer disease.